Evidence map›Paper›PMID 40123277›Full record

ReviewCancer science2025

Opportunities to Modulate Tumor Ecosystem Toward Successful Glioblastoma Immunotherapy.

Mariko Takahashi, Darina Mukhamejanova, Himani Jasewicz, Nandini Acharya, James J Moon, Toshiro Hara

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mariko TakahashiDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan, USA.
Darina MukhamejanovaBiointerfaces Institute, University of Michigan, Ann Arbor, Michigan, USA.
Himani JasewiczBiointerfaces Institute, University of Michigan, Ann Arbor, Michigan, USA.
Nandini AcharyaPelotonia Institute for Immuno-Oncology, OSUCCC-James, The Ohio State University, Columbus, Ohio, USA.
James J MoonDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan, USA.
Toshiro HaraBiointerfaces Institute, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-4389-3393

Funding

Biomaterials for modulating the gut microbiome for immune activationR01CA271799 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI James J. Moon, Deepak Nagrath · 2022 to 2026
$2.7M
Novel nano-vaccine technology for inducing immunity against gliomasR01NS122536 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G, MOON, JAMES J. · 2021 to 2025
$2.6M
Novel biomaterials for IBD treatmentR01DK125087 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAMADA, NOBUHIKO, MOON, JAMES J. · 2020 to 2023
$2.5M
American Brain Tumor AssociationAOU NIH HHSBrain Research FoundationFrankel Innovation Initiative at the University of MichiganNCI NIH HHS R01 CA271799NIDDK NIH HHS R01 DK125087NINDS NIH HHS R01 NS122536Rogel Cancer Center, University of MichiganSeth M Boyer Foundation
6 · The paper itself

Abstract

Over the past decade, the failure of multiple clinical trials has confirmed the need for a systematic and comprehensive understanding of glioblastoma (GBM). Current immunotherapies aiming to harness the immune system to achieve anti-tumor effects remain largely ineffective, highlighting the complexities of the GBM microenvironment. However, our recent understanding of immune niches within the central nervous system provides both opportunities and challenges in translating these insights into successful immunotherapy implementation. We discuss these strategies, including targeting multiple antigens within the heterogeneous GBM microenvironment, identifying new druggable targets to abrogate immunosuppression, and understanding niche-specific immune cell functionality to modulate tumor-immune-stroma interactions.

Indexed as

Brain NeoplasmsGlioblastomaImmunotherapyTumor MicroenvironmentAnimalsHumans

Identifiers

PMID40123277
PMCPMC12127102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.